p53 gene therapy using RNA interference

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Berindan Neagoe, Ioana ^a,b   Balacescu, O ^a   Burz, C ^b   Braicu, C ^a   Balacescu, L ^a   Tudoran, O ^a   Cristea, V ^a   Irimie, A ^a,b  

^a Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Apoptosis; Cancer; p53; Restoration; RNA interference; Transcription

Indexed keywords

PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; CANCER GENE THERAPY; CELL CYCLE REGULATION; CONFERENCE PAPER; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL DIVISION; GENE THERAPY; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, GENETIC; NEOPLASMS; RNA INTERFERENCE; TRANSCRIPTION, GENETIC;

EID: 70350061176     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Bykov VJ, Issaeva N, Shilov A et al. Restoration of the tumor suppressor function to mutant p53 by low molecular-weight compound. Nat Medicine 2002; 8: 282-288. (Pubitemid 34250107)
2. Issaeva N, Bozko P, Enge M et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Medicine 2004; 10: 1321-1328. (Pubitemid 40022713)
3. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome C. Cell Death Differ 2000; 7: 1166-1173.
4. Bykov VJ, Issaeva N, Zache N et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analog. J Biol Chem 2005; 280: 30384-30391. (Pubitemid 41216221)
5. Wang W, Rastinejad F, El-Deiry WS. Restoring p53-dependent tumor suppression. Cancer Biol Ther 2003; 2(4 Suppl 1): S55-63.
6. Shibue T, Suzuki S, Okamoto H et al. Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic pathways. EMBO J 2006; 25: 4952-4962. (Pubitemid 44607039)
7. Sjostrom-Mattson J, von Boguslawski K, Bengtsson NO, Mjaaland I, Salmenkivi K, Blomqvist C. The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer. Acta Oncol 2009; 6: 742-749.
8. Bottani S, Grammaticos B. Analysis of a minimal model for p53 oscillations. J Theor Biol 2007; 249: 235-245. (Pubitemid 47632640)
9. Zambetti GP. The p53 mutation "gradient effect" and its clinical implications. Review. J Cell Physiol 2007; 213: 370-373.
10. Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M. The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res 2005; 65: 10255-10264. (Pubitemid 41743717)
11. Sparapani F, Bisio A, Del Vescovo A, Tonelli C, Ciribilli Y, De Sanctis V. MicroRNA-based, p53 dependent post-transcriptional circuits: mechanisms, target and interindividual variation. J Pezcoller Foundation 2009; 19: 28-29.
12. Piccirillo S, Filomeni G, Brune B, Rotilio G, Ciriolo MR. Redox mechanisms involved in the selective activation of Nrf2-mediated resistance versus p53-dependent apoptosis in adenocarcinoma gastric cells. J Biol Chem 2009 (Published as Papers in Press, July 30, 2009 M109.014837).
13. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: Key molecular signaling pathways and therapy targets. Acta Oncol 2009; 6: 811-821.
14. Shwu-Yuan Wu, Cheng-Ming Chiang. Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding EMBO J 2009; 28: 1246-1259.
15. Court DL, Sawitzke JA, Thomas LC. Genetic engineering using homologous recombination. Annu Rev Genet 2002; 36: 361-388.
16. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10: 501-514. (Pubitemid 44854749)
17. Momand J, Jung D, Wilcznski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26: 3453-3459.
18. Tovar C, Rosinski J, Filipovic Z et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006; 103: 1888-1893. (Pubitemid 43228788)
19. Binder BR. A novel application for murine double minute 2 antagonists: the p53 tumor suppressor network also controls angiogenesis. Circ Res 2007; 100: 13-14.
20. Tesniere A, Panaretakis T, Kepp O et al. Molecular characteristics of immunogenic cancer cell death .Cell Death Differentiation 2008; 15: 3-12.
21. Shangary S, Qin D, McEachern D et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105: 3933-3938. (Pubitemid 351723502)
22. Naldini A, Carrara F. Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 2005; 4: 3-8.
23. Schoeffner DJ, Matheny SL, Akahane T et al. VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab Invest 2005; 85: 608-623. (Pubitemid 40675442)
24. Tudoran O, Berindan-Neagoe I, Balacescu O et al. VEGF expression level in HeLa cell lines modulated by silence interference RNA. Roman Biotehnol Lett 2009; 6 (ahead of print).
25. Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell death and the ensuing immune response. Cell Death Differentiation 2008; 15: 21-28. (Pubitemid 350286169)
26. Baudin A, Ozier-Kalogeropoulos O, Denouel A, Lacroute F, Cullin C. A simple and efficient method for direct gene deletion in Saccharomyces cerevisiae. Nucleic Acids Res 1993; 21: 3329-3330. (Pubitemid 23230516)
27. Sonoda E, Morrison C, Yamashita YM, Takata M, Takeda S. Reverse genetic studies of homologous DNA recombination using the chicken B-lymphocyte line, DT40. Philos Trans R Soc Lond B Biol Sci 2001; 356: 111-117. (Pubitemid 32575595)
28. Buerstedde JM, Arakawa H, Watahiki A et al. The DT40 web site: sampling and connecting the genes of a B cell line. Nucleic Acids Res 2002; 30: 230-231. (Pubitemid 34679550)
29. Ledermann B. Embryonic stem cells and gene targeting. Exp Physiol 2000; 209: 603-613.
30. Hannon GJ. RNA interference. Nature 2002; 418: 244-251.
31. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811. (Pubitemid 28099681)
32. Gonczy P, Echeverri C, Oegema K et al. Functional genomic analysis of cell division in C. elegans using RNAi of genes on chromosome III. Nature 2000; 408: 325-330.
33. Fraser AG, Kamath RS, Zipperlen P, Martinez-Campos M, Sohrmann M, Ahringer J. Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 2000; 408: 325-330.
34. Kamath RS, Fraser AG, Dong Y et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003; 421: 231-237. (Pubitemid 36139121)
35. Li S, Rosenberg JE, Donjacour AA et al. Rapid Inhibition of Cancer Cell Growth Induced by Lentiviral Delivery and Expression of Mutant-Template Telomerase RNA and Antitelomerase Short-Interfering RNA. Cancer Res 2004; 64: 4833-4840. (Pubitemid 38924527)
36. Okamura K, Ishizuka A, Siomi H, Siomi MC. Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev 2004; 18: 1655-1666. (Pubitemid 38938183)
37. Ni Q, Chen Z, Yao HP, Yang ZG, Liu KZ, Wu LL. Inhibition of human La protein by RNA interference downregulates hepatitis B virus mRNA in 2.2.15 cells. World J Gastroenterol 2004; 10: 2050-2054. (Pubitemid 39106956)
38. Ventura A, Meissner A, Dillon CP et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004; 101: 10380-10385. (Pubitemid 38924934)
39. Fukagawa T, Nogami M, Yoshikawa M et al. Dicer is essential for formation of the heterochromatin structure in vertebrate cells. Nat Cell Biol 2004; 6: 696-697. (Pubitemid 39144485)
40. Gottesman S. Small RNAs Shed Some Light. Cell 2004; 118: 1-2.
41. Steinmetz R, Wagoner HA, Zeng P et al. Mechanisms Regulating the Constitutive Activation of the ERK Signaling Pathway in Ovarian Cancer and the Effect of RNAi for ERK1/2 on Cancer Cell Proliferation. Mol Endocrinol 2004; 18: 2570-2582.
42. Okoshi R, Ozaki T, Yamamoto H et al. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 2008; 283: 3979-3987.
43. Milhavet O, Gary DS, Mattson MP. RNA interference in biology and medicine. Pharmacol Rev 2003; 55: 629-648. (Pubitemid 37500523)
44. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature 2009; 457: 426-433.
45. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002; 32: 107-108. (Pubitemid 34977204)
46. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH. Delivery of RNA interference. Cell Cycle 2006; 5: 2103-2109.